Effects of PF-06412562 on Value-based Decision-making in Healthy Individuals
Status:
Completed
Trial end date:
2017-12-20
Target enrollment:
Participant gender:
Summary
Numerous psychiatric and neurodegenerative diseases like schizophrenia, dependency on drugs
of abuse, depression and Parkinson's disease are related to motivational and cognitive
deficits in value-based decision making, which frequently persist even after a successful
pharmacological treatment. According to current neurobiologic models, cortical dopamine D1
receptors play a crucial role in taking value-based decisions. In this study, it will be
investigated whether value-based decisions in healthy volunteers can be improved by
stimulation of D1-receptors. For this purpose, a newly developed dopamine D1-agonist will be
used, which selectively increases the activities of frontal D1- and D5-receptors. In this
double-blind, randomized, placebo-controlled study, the effects of different single doses of
PF-06412562, a not yet licensed D1-agonist, on value-based decision making will be compared
with placebo. The use of different dosage strengths will allow to investigate a potential
relationship between the extent of activity of the D1-receptor and its influence on
behavioral indices.
Therefore, four parallel groups will be investigated. Each participant takes in a single dose
of either PF-06412562 in different doses or placebo. A screening exam will be carried out 1-3
weeks before the drug intake, and a follow-up examination will be carried out approx. 1 week
after the drug intake. At all 3 visits in the study centre, several tests for the
investigation of value-based decision making will be carried out.